Tech Company Financing Transactions
SwanBio Therapeutics Funding Round
SwanBio Therapeutics, based in Bala Cynwyd, secured $52 million in investment from Partners Innovation Fund, Syncona and private investors.
Transaction Overview
Company Name
Announced On
4/24/2020
Transaction Type
Venture Equity
Amount
$52,000,000
Round
Series A
Investors
Syncona (Chris Hollowood)
Proceeds Purpose
The funding will help rapidly progress the understanding and development of adeno-associated virus (AAV) based gene therapies, advance manufacturing and development capabilities and allow the execution of a robust hiring plan to meet the demands of the pipeline.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
150 Monument Rd. 207
Bala Cynwyd, PA 19004
USA
Bala Cynwyd, PA 19004
USA
Phone
Undisclosed
Website
Email Address
Overview
SwanBio Therapeutics is a gene therapy company developing leading-edge medicines to deliver dramatic clinical efficacy for the treatment of neurological diseases. We are driven by an unrelenting passion to solve difficult challenges, and a belief that meaningful discovery is born of curiosity, collaboration, and compassion.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Thomas Anderson
Chief Scientific Officer
Karen Kozarsky
Chief Technical Officer
Rebecca Dabora
Co-Founder
Florian Eichler
President
Rachel Salzman
VP - General Counsel
Michael Alexander
VP - Human Resources
Carolyn Carroll
Browse more venture capital transactions:
Prev: 4/24/2020: AvidXchange venture capital transaction
Next: 4/24/2020: Comet.ml venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to document funding rounds that are announced publicly. VC transactions reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs